Armata Pharmaceuticals (ARMP) Gains from Investment Securities (2015 - 2026)
Armata Pharmaceuticals (ARMP) reported Gains from Investment Securities of $20.6 million for Q1 2026, up 9590.14% sequentially from $213000.0 in Q1 2015.
Armata Pharmaceuticals (ARMP) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Armata Pharmaceuticals (ARMP) has 2 years of Gains from Investment Securities data on file, last reported at $20.6 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $20.6 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (changed N/A YoY), and the FY2013 full-year result was $759000.0, changed N/A from the prior year.
- Gains from Investment Securities rose to $20.6 million in Q1 2026, from $213000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $20.6 million in Q1 2026 to a low of $20.6 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Armata Pharmaceuticals | 173.88 Mn | 169.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.64 Mn |
| Mar 31, 2026 | 20.64 Mn |
| Mar 31, 2015 | 213,000.00 |
| Mar 31, 2015 | 213,000.00 |